Skip to main content

Table 2 Utility values, utility decrease and costs assigned to health states and adverse drug reactions (ADR)

From: Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

 

Utility values

Costs in €

Health State

Utility

Monthly Cost

Healthy

0.86 [17]

0

Remission

0.81 [17]

Direct: 35‡

Indirect: 173†

Depressive Episode

0.57 [17]

Direct: 190‡

Indirect: 380†

Adverse Drug Reaction

Utility Decrease

Monthly cost*

Constipation

0.065 [33]

12.5

Diarrhoea

0.044 [33]

5.5

Dyspepsia

0.086 [33]

12.0

Nausea

0.065 [33]

6.0

Somnolence

0.085 [33]

0.0

Headache

0.115 [33]

2.8

Sexual dysfunction

0.049 [33]

44.0

Sleep difficulties

0.08095 [34]

54.0

Discontinuation Symptoms

0.065 [33]

52.0

Study Medication

Expected Utility Decrease due to ADR §

Monthly medication cost ††

Agomelatine

0.026

60.27

Venlafaxine

0.039

18.03

Escitalopram

0.035

56.31

Fluoxetine

0.026

21.31

Sertraline

0.020

17.35

Generic Venlafaxine

 

14.38

Generic Escitalopram

 

45.60

Generic Fluoxetine

 

14.37

Generic Sertraline

 

10.81

  1. § Computed based on frequency of ADR and Utility Decrease assigned to each ADR.
  2. ‡ Computed based on Experts’ opinion & Government Gazette.
  3. † Computed based on Experts’ opinion & Gross Domestic Product from National Statistics Service.
  4. *Computed based on Experts’ opinion and Drug Price Bulletin.
  5. †† Drug Price Bulletin.